RU2724338C2 - Фармацевтическая комплексная композиция, включающая амлодипин, лозартан и розувастатин - Google Patents

Фармацевтическая комплексная композиция, включающая амлодипин, лозартан и розувастатин Download PDF

Info

Publication number
RU2724338C2
RU2724338C2 RU2018103213A RU2018103213A RU2724338C2 RU 2724338 C2 RU2724338 C2 RU 2724338C2 RU 2018103213 A RU2018103213 A RU 2018103213A RU 2018103213 A RU2018103213 A RU 2018103213A RU 2724338 C2 RU2724338 C2 RU 2724338C2
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
acceptable salt
rosuvastatin
mixture
losartan
Prior art date
Application number
RU2018103213A
Other languages
English (en)
Russian (ru)
Other versions
RU2018103213A (ru
RU2018103213A3 (ko
Inventor
Йонг Ил Ким
Хо Таек Им
Хиук Дзун ЧО
Йоунгсу ЙООН
Дзае Хиун Парк
Дзонг Соо Воо
Original Assignee
Ханми Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ханми Фарм. Ко., Лтд. filed Critical Ханми Фарм. Ко., Лтд.
Publication of RU2018103213A publication Critical patent/RU2018103213A/ru
Publication of RU2018103213A3 publication Critical patent/RU2018103213A3/ru
Application granted granted Critical
Publication of RU2724338C2 publication Critical patent/RU2724338C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2018103213A 2015-06-30 2016-06-29 Фармацевтическая комплексная композиция, включающая амлодипин, лозартан и розувастатин RU2724338C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2015-0093714 2015-06-30
KR20150093714 2015-06-30
PCT/KR2016/006977 WO2017003186A1 (en) 2015-06-30 2016-06-29 Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin

Publications (3)

Publication Number Publication Date
RU2018103213A RU2018103213A (ru) 2019-07-31
RU2018103213A3 RU2018103213A3 (ko) 2019-12-09
RU2724338C2 true RU2724338C2 (ru) 2020-06-23

Family

ID=57608904

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018103213A RU2724338C2 (ru) 2015-06-30 2016-06-29 Фармацевтическая комплексная композиция, включающая амлодипин, лозартан и розувастатин

Country Status (6)

Country Link
KR (2) KR20170003459A (ko)
CN (2) CN108156807A (ko)
MX (2) MX2017014311A (ko)
PH (1) PH12017501986A1 (ko)
RU (1) RU2724338C2 (ko)
WO (1) WO2017003186A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019022436A2 (ko) * 2017-07-27 2019-01-31 에리슨제약(주) Nep 저해제 및 베타-차단제를 포함하는 약제학적 조성물
KR20190043076A (ko) * 2017-10-17 2019-04-25 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제
CN108245516B (zh) * 2017-11-09 2019-04-12 浙江京新药业股份有限公司 一种含瑞舒伐他汀钙的药物组合物及其制备方法
CN109464407A (zh) * 2018-12-27 2019-03-15 成都恒瑞制药有限公司 瑞舒伐他汀钙快速释放制剂及其制备方法
KR102500643B1 (ko) * 2019-04-18 2023-02-16 한미약품 주식회사 에제티미브 및 로사르탄을 포함하는 약제학적 복합제제
KR20220026641A (ko) * 2020-08-25 2022-03-07 주식회사 대웅제약 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
WO2009154810A2 (en) * 2008-02-25 2009-12-23 Dr. Reddy's Laboratories Ltd. Delivery systems for multiple active agents
WO2010085047A2 (en) * 2009-01-23 2010-07-29 Hanmi Pharm. Co., Ltd. Solid pharmaceutical composition comprising amlodipine and losartan
WO2013154390A1 (en) * 2012-04-13 2013-10-17 Hanmi Pharm. Co., Ltd. Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same
WO2015080433A1 (en) * 2013-11-29 2015-06-04 Hanmi Pharm. Co., Ltd. Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
EP2086519B1 (en) * 2006-10-30 2017-06-21 HanAll Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
CN101690816A (zh) * 2009-08-16 2010-04-07 王丽燕 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
WO2009154810A2 (en) * 2008-02-25 2009-12-23 Dr. Reddy's Laboratories Ltd. Delivery systems for multiple active agents
WO2010085047A2 (en) * 2009-01-23 2010-07-29 Hanmi Pharm. Co., Ltd. Solid pharmaceutical composition comprising amlodipine and losartan
WO2013154390A1 (en) * 2012-04-13 2013-10-17 Hanmi Pharm. Co., Ltd. Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same
WO2015080433A1 (en) * 2013-11-29 2015-06-04 Hanmi Pharm. Co., Ltd. Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin

Also Published As

Publication number Publication date
KR20170003459A (ko) 2017-01-09
RU2018103213A (ru) 2019-07-31
MX2021005210A (es) 2021-06-18
PH12017501986A1 (en) 2018-03-19
WO2017003186A1 (en) 2017-01-05
KR20180044873A (ko) 2018-05-03
CN112933093A (zh) 2021-06-11
RU2018103213A3 (ko) 2019-12-09
CN108156807A (zh) 2018-06-12
MX2017014311A (es) 2018-03-07

Similar Documents

Publication Publication Date Title
RU2724338C2 (ru) Фармацевтическая комплексная композиция, включающая амлодипин, лозартан и розувастатин
TWI649099B (zh) 包含氨氯地平（ａｍｌｏｄｉｐｉｎｅ）、洛沙坦（ｌｏｓａｒｔａｎ）及羅舒伐他汀（ｒｏｓｕｖａｓｔａｔｉｎ）之藥學組合物配方
JP5658172B2 (ja) アムロジピン及びロサルタンを含む固形薬剤学的組成物及びその製造方法
US7741374B1 (en) Methods of use of fenofibric acid
JP6068765B2 (ja) 薬学的複合製剤
KR102246657B1 (ko) 타다라필 및 탐수로신을 함유하는 약학적 캡슐 복합 제제
TWI714560B (zh) 包含安洛待平（ａｍｌｏｄｉｐｉｎｅ）、洛沙坦（ｌｏｓａｒｔａｎ）及氯薩利酮（ｃｈｌｏｒｔｈａｌｉｄｏｎｅ）的醫藥複合調配物
WO2013100630A1 (en) Fixed dose combination formulation comprising losartan, amlodipine and hydrochlorothiazide
KR20190045286A (ko) 로수바스타틴 및 에제티미브를 포함하는 제약 조성물 및 그의 제조 방법
KR102569271B1 (ko) 에제티미브 및 로수바스타틴을 포함하는 약제학적 복합제제
EA037041B1 (ru) Пероральные фармацевтические составы для лечения связанных с диабетом макрососудистых и микрососудистых осложнений
AU2011339150B2 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
RU2674978C2 (ru) Фармацевтическая композиция N-[5-[2-(3,5-диметоксифенил)этил]-2H-пиразол-3-ил]-4-[(3R,5S)-3,5-диметилпиперазин-1-ил]бензамида
WO2019230937A1 (ja) 溶出性に優れた経口固形製剤
TWI827828B (zh) 包含依澤替米貝(ezetimibe)及洛沙坦(losartan)之藥學組合製劑